M&A / Deals Cardio biotech Kardigan binds off $400M upsized IPO BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.CardiovascularRead full story pharminent June 18, 2026 (Last updated: June 19, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Cardiovascular Read full story Post navigation Previous: GSK claims FDA okay for first oral carbapenem antibioticNext: Heart drug biotech Kardigan raises $400m in upscaled IPO Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026